06 – Exact Sciences Symposium
Free entry upon registration
Exact Sciences is an American molecular diagnostics company specializing in the early detection and monitoring of cancer. It develops precision genomic tests to help personalize treatment, particularly for breast cancer.
Programme détaillé
Oncotype DX Breast Recurrence Score® Test
The Oncotype DX test is a biological test that analyzes the DNA of a breast cancer tumor. It helps doctors determine whether chemotherapy is really necessary after surgery.
It is intended for women with early-stage, hormone-sensitive (HR+)
breast cancer with no or few affected lymph nodes.
By studying 21 genes present in the tumor, the test assesses the risk of recurrence and determines whether chemotherapy will be beneficial.
This test is particularly useful in situations where the decision to undergo chemotherapy is unclear. It helps avoid unnecessary treatment and helps doctors make a more accurate decision when other conventional tests are insufficient. The test is performed directly on the tumor sample.
Clinical value and impact
More than 1.8 million patients evaluated, with 1.48 million at low risk (low score), often avoiding chemotherapy. The only test validated as both prognostic and predictive, recommended by leading societies (NCCN, ASCO, ESMO).
Fairness & reliability
JAMA Oncology publication in April 2025: confirmation of the test’s reliability regardless of ethnic origin, based on a large clinical sample (> 171,000 patients).
Refreshments will be served during the symposium.